Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
- 656 Downloads
Symptom occurrence has been shown to predict treatment course and survival in patients with solid tumors. Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms. Currently, no instrument exists that measures both neurologic and cancer-related symptoms.
Patients diagnosed with PBT participated in this study. Data was collected at one point in time and included demographic and clinical factors, and the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients.
Two hundred and one patients participated in this study. Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22 (13 core, 9 brain tumor items). Regression analysis showed more than half (56%) of the variability in symptom severity was explained by brain module items. The MDASI-BT measures six underlying constructs including affective, cognitive, focal neurologic deficit, constitutional, generalized symptom, and a gastrointestinal related factor. The internal consistency (reliability) of the instrument was 0.91. The MDASI-BT was sensitive to disease severity based on performance status (P<0.001), tumor recurrence (P<0.01), and mean symptom interference (P<0.001).
The 22 item MDASI-BT demonstrated validity and reliability in patients with PBT. This instrument can be used to identify symptom occurrence throughout the disease trajectory and to evaluate interventions designed for symptom management.
Keywordsbrain tumors self-report instruments symptoms
Unable to display preview. Download preview PDF.
This study was supported by the Oncology Nursing Society/American Brain Tumor Association Neuro-oncology Research Grant and a grant from Pfizer Pharmaceuticals.
- 3.Fobair P, Mackworth N, Varghese A, Prados M: Quality of life issues among 200 brain tumor patients treated at the University of California in San Francisco, interviewed 1988. Presented at the Brain Tumor Conference: a living resource guide. San Francisco, California, March 3–5, 1990Google Scholar
- 10.Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F The middle-range theory of unpleasant symptoms: an update. Adv Nurs Sci 1997;19(3):14–27Google Scholar
- 23.McKeran RO, Thomas DGT: The clinical study of glioma. In: Thomas DGT, Graham DL., ed. Brain Tumors: Scientific Basis: Clinical Investigation and Current Therapy Lippincott Baltimore 1980:194–230Google Scholar
- 34.Cleeland CS, Reyes-Gibby CC When is it justified to treat symptoms? Measuring symptom burden. Oncology (Williston Park) 2002;16(9 Suppl 10):64–70Google Scholar
- 39.Lynn MR Determination and quantification of content validity. Nurs Res 1985;35(6):382–385Google Scholar
- 42.Aldenderfer MS, Blashfield RK Cluster Analysis. Sage Publications, London, 1984Google Scholar
- 43.Harman HH: Modern Factor Analysis, 2. University of Chicago Press Chicago, 1967Google Scholar
- 46.Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157–165CrossRefPubMedGoogle Scholar